Skip to main content

Table 3 Adverse event disutilities

From: Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland

Event in VN arm Utility decrement Duration (months) Proportion of patients
Cataract 0.14 1.0 15%
Eye inflammation 0.30 3.6 10%
Increased IOP 0.10a 1.0 20%
  1. a Assumption, as no disutility data associated with increased IOP were identified.
  2. AE adverse event, IOP increased intraocular pressure.